|
注册号: Registration number: |
ChiCTR2600124620 |
|
最近更新日期: Date of Last Refreshed on: |
2026-05-14 14:55:38 |
|
注册时间: Date of Registration: |
2026-05-14 00:00:00 |
|
注册号状态: |
预注册 |
|
Registration Status: |
Prospective registration |
|
注册题目: |
基于HIS系统河南地区皮肤病流行病学特征、临床用药特征研究 |
|
Public title: |
Study on the Epidemiological Characteristics and Clinical Medication Characteristics of Dermatosis in Henan Province Based on HIS |
|
注册题目简写: |
|
|
English Acronym: |
|
|
研究课题的正式科学名称: |
基于HIS系统河南地区皮肤病流行病学特征、临床用药特征研究 |
|
Scientific title: |
Study on the Epidemiological Characteristics and Clinical Medication Characteristics of Dermatosis in Henan Province Based on HIS |
|
研究课题代号(代码): Study subject ID: |
|
|
在二级注册机构或其它机构的注册号: The registration number of the Partner Registry or other register: |
|
申请注册联系人: |
刘颖 |
研究负责人: |
李薇薇 |
|
Applicant: |
Ying Liu |
Study leader: |
Weiwei Li |
|
申请注册联系人电话: Applicant telephone: |
+86 188 3435 8796 |
研究负责人电话:
Study leader's |
+86 155 3791 0701 |
|
申请注册联系人传真 : Applicant Fax: |
研究负责人传真: Study leader's fax: |
||
|
申请注册联系人电子邮件: Applicant E-mail: |
hnliuying3@eastchinapharm.com |
研究负责人电子邮件: Study leader's E-mail: |
448140028@qq.com |
|
申请单位网址(自愿提供): Applicant website(voluntary supply): |
研究负责人网址(自愿提供): Study leader's website(voluntary supply): |
||
|
申请注册联系人通讯地址: |
河南省郑州市管城回族区紫荆山路182号正商蓝海广场2栋1301 |
研究负责人通讯地址: |
洛阳市涧西区西苑路36号 |
|
Applicant address: |
Room 1301, Building 2, Zhengshang Lanhai Plaza, No. 182 Zijingshan Road, Guancheng Hui District, Zhengzhou City, Henan Province, China |
Study leader's address: |
No. 36 Xiyuan Road, Jianxi District, Luoyang City, Henan Province, China |
|
申请注册联系人邮政编码: Applicant postcode: |
研究负责人邮政编码: Study leader's postcode: |
||
|
申请人所在单位: |
杭州中美华东制药有限公司 |
||
|
Applicant's institution: |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
||
|
研究负责人所在单位: |
洛阳市东方人民医院 |
||
|
Affiliation of the Leader: |
Luoyang Dongfang People's Hospital |
||
|
是否获伦理委员会批准: |
是 |
||
|
Approved by ethic committee: |
Yes |
||
|
伦理委员会批件文号: Approved No. of ethic committee: |
2026-001-01 |
伦理委员会批件附件: Approved file of Ethical Committee: |
查看附件View |
|
批准本研究的伦理委员会名称: |
洛阳市东方人民医院药物临床试验伦理委员会 |
||
|
Name of the ethic committee: |
Ethics Committee of Drug Clinical Trials of Luoyang Dongfang People's Hospital |
||
|
伦理委员会批准日期: Date of approved by ethic committee: |
2026-02-06 00:00:00 | ||
|
伦理委员会联系人: |
李佳鑫 |
||
|
Contact Name of the ethic committee: |
Jiaxin Li |
||
|
伦理委员会联系地址: |
洛阳市涧西区西苑路36号 |
||
|
Contact Address of the ethic committee: |
No. 36 Xiyuan Road, Jianxi District, Luoyang City, Henan Province, China |
||
|
伦理委员会联系人电话: Contact phone of the ethic committee: |
+86 379 6497 6977 |
伦理委员会联系人邮箱: Contact email of the ethic committee: |
|
|
研究实施负责(组长)单位: |
洛阳市东方人民医院 |
||||||||||||||||||||||
|
Primary sponsor: |
Luoyang Dongfang People's Hospital |
||||||||||||||||||||||
|
研究实施负责(组长)单位地址: |
洛阳市涧西区西苑路36号 |
||||||||||||||||||||||
|
Primary sponsor's address: |
No. 36 Xiyuan Road, Jianxi District, Luoyang City, Henan Province, China |
||||||||||||||||||||||
|
试验主办单位(项目批准或申办者): Secondary sponsor: |
|
||||||||||||||||||||||
|
经费或物资来源: |
杭州中美华东制药有限公司 |
||||||||||||||||||||||
|
Source(s) of funding: |
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. |
||||||||||||||||||||||
|
研究疾病: |
皮肤病 |
||||||||||||||||||||||
|
Target disease: |
Dermatosis |
||||||||||||||||||||||
|
研究疾病代码: |
|
||||||||||||||||||||||
|
Target disease code: |
|
||||||||||||||||||||||
|
研究类型: |
观察性研究 |
||||||||||||||||||||||
|
Study type: |
Observational study |
||||||||||||||||||||||
|
研究所处阶段: |
回顾性研究 | ||||||||||||||||||||||
|
Study phase: |
Retrospective study |
||||||||||||||||||||||
|
研究设计: |
横断面 |
||||||||||||||||||||||
|
Study design: |
Cross-sectional |
||||||||||||||||||||||
|
研究目的: |
描述河南省医疗机构皮肤病患者的流行病学分布特征与临床用药模式,分析重点皮肤病,为区域皮肤病防控策略和临床合理用药提供参考依据。 |
||||||||||||||||||||||
|
Objectives of Study: |
To describe the epidemiological distribution characteristics and clinical medication patterns of dermatology patients in medical institutions in Henan Province, analyze priority skin diseases, and provide references for regional skin disease prevention and control strategies as well as rational clinical drug use. |
||||||||||||||||||||||
|
药物成份或治疗方案详述: |
|
||||||||||||||||||||||
|
Description for medicine or protocol of treatment in detail: |
|
||||||||||||||||||||||
|
纳入标准: |
|||||||||||||||||||||||
|
Inclusion criteria |
|||||||||||||||||||||||
|
排除标准: |
1.住院天数小于1天(日间病房或当天出入院); 2.关键信息缺失(如无明确诊断、无用药记录); 3.数据记录存在明显逻辑错误或重复。 4.合并诊断包括恶性肿瘤、重要脏器(心、肝、肺、肾)功能衰竭,且处于急性发作期。 5.本次住院主要因合并其他皮肤病进行治疗,可能使目标疾病的用药特征分析产生混杂。 |
||||||||||||||||||||||
|
Exclusion criteria: |
1. Hospital stay less than 1 day (day ward or same-day admission and discharge); 2. Missing key information (e.g., no definite diagnosis, no medication records); 3. Obvious logical errors or duplication in data records; 4. Concurrent diagnosis includes malignant tumors or functional failure of vital organs (heart, liver, lung, kidney) in the acute exacerbation phase; 5. The primary reason for this hospitalization is treatment for other concomitant skin diseases, which may cause confounding in the analysis of medication characteristics for the target disease. |
||||||||||||||||||||||
|
研究实施时间: Study execute time: |
从 From 2026-03-31 00:00:00至 To 2028-03-31 00:00:00 |
征募观察对象时间: Recruiting time: |
从 From 2026-05-31 00:00:00 至 To 2028-03-31 00:00:00 |
|
干预措施: Interventions: |
|
|
研究实施地点: Countries of recruitment and research settings: |
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
测量指标: Outcomes: |
|
|
采集人体标本:
Collecting sample(s)
|
|
|
征募研究对象情况: Recruiting status: |
尚未开始 Not yet recruiting |
年龄范围: Participant age: |
|
||||||
|
性别: |
男女均可 |
Gender: |
Both |
||||||
|
随机方法(请说明由何人用什么方法产生随机序列): |
无 |
||||||||
|
Randomization Procedure (please state who generates the random number sequence and by what method): |
none |
||||||||
|
是否公开试验完成后的统计结果: Calculated Results after the Study Completed public access: |
公开/Public |
|
盲法: |
|
|
Blinding: |
|
|
试验完成后的统计结果(上传文件): |
|
|
Calculated Results after
|
|
|
是否共享原始数据: IPD sharing |
否No |
|
共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址): |
无 |
|
The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url): |
none |
|
数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC: |
EDC |
|
Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture: |
EDC |
|
数据与安全监察委员会: Data and Safety Monitoring Committee: |
无/No |